Results 131 to 140 of about 121,384 (261)

Microbial Hydrolysates as Amino Acid Source in Cell Culture Media for Cellular Agriculture

Biotechnology and Bioengineering, EarlyView.
ABSTRACT The high cost of cultivation media remains one of the barriers to the commercialization of cultivated meat. Current serum‐free media reduce reliance on fetal bovine serum but only achieve modest cost savings. Especially at larger scales (> 20 m3), pharmaceutical‐grade amino acids and recombinant proteins remain major cost drivers.
Jelle C. Hoek, Jean‐Marc Daran, Marieke E. Klijn, Marcel A. Vieira‐Lara   +3 more
wiley   +1 more source

Epigenomic regulation of neural crest differentiation in human-induced pluripotent stem cells. [PDF]

iScience
Mukae K, Shindo M, Shi T, Onuki R, Yamashita S, Hattori N, Ushijima T, Ohira M, Kamijo T.   +8 more
europepmc   +1 more source

High Cell Density Cultivation of HEK293 Cells Using a 2L Membrane‐Stirred Bioreactor

Biotechnology and Bioengineering, EarlyView.
ABSTRACT The use of perfusion systems for the continuous cultivation of animal cells at high cell density (HCD) for the production of recombinant proteins, viruses, and viral vectors has many advantages. Besides an enhancement of volumetric productivity and high cell viability, the product quality can be improved through a steady‐state environment ...
Lennart Jacobtorweihe, Yasemin van Heuvel, Kathrina Scheiermann, Patrick Bongartz, Yvonne Genzel, Udo Reichl   +5 more
wiley   +1 more source

Patient-derived induced pluripotent stem cells for precision modelling of monogenic beta cell disorders. [PDF]

Front Endocrinol (Lausanne)
Deng L, Krishnamurthy M.
europepmc   +1 more source

Drug‐coated balloons: From conventional designs to next‐generation innovations in vascular therapy

BMEMat, EarlyView.
This review traces the evolution of drug‐coated balloons (DCBs) from conventional designs to next‐generation platforms. We highlight innovations in balloon engineering, coating technologies, and therapeutic agents that enhance localized drug delivery while addressing challenges in efficiency, safety, and biocompatibility for vascular and emerging non ...
Lu Zhang, Jiawei Cui, Jin Wang, Manfred F. Maitz, Rifang Luo, Yunbing Wang   +5 more
wiley   +1 more source

Single-cell transcriptomics-informed induced pluripotent stem cells differentiation to tenogenic lineage. [PDF]

Elife
Papalamprou A, Yu V, Jiang W, Sheyn J, Stefanovic T, Chen A, Castaneda C, Chavez M, Sheyn D.   +8 more
europepmc   +1 more source

Integrated spherical nucleic acid nanoreactor mobilizes targeted PD‐L1 proteolysis and cuproptosis for robust breast cancer immunotherapy

BMEMat, EarlyView.
This study provides an integrated spherical nucleic acid nanoreactor (denoted as AMCuD) for targeted PD‐L1 degradation and chemo‐dynamically enhanced cuproptosis to synergically elicit robust immunotherapy against the triple‐negative breast cancer (TNBC) growth, recurrence and metastasis.
Ningxi Li, Honglin Huang, Qianyi Zeng, Li Zeng, Ziman Yang, Jinyang Shen, Shun Li, Hong Yang, Yiyao Liu, Chunhui Wu   +9 more
wiley   +1 more source

Engineering of functional auditory neurons from human induced pluripotent stem cells. [PDF]

Mil Med Res
Jeong M, Vattino LG, Djurisic M, Rose KP, Hyakusoku H, Spasic S, Ma XJ, Mohri H, Hertzano R, Takesian AE, Stankovic KM.   +10 more
europepmc   +1 more source

Toward clone‐on‐a‐chip: Ethical and legal considerations for organ‐on‐a‐chip evolution

BMEMat, EarlyView.
The term “clone‐on‐a‐chip (CoC)” is introduced as a conceptual warning for personalized organ‐on‐a‐chip platforms and not to suggest technological feasibility, where a CoC ethical discussion extends beyond issues arising from the requirements for informed consent, property rights, commercialization efforts, and cell sourcing to include potentially ...
Muhammed Erkan Karabekmez, Aliakbar Ebrahimi, Hamed Ghorbanpoor, Nicole Bassous, Su Ryon Shin, Yu Shrike Zhang, Huseyin Avci   +6 more
wiley   +1 more source

APOE4 Alters Early Transcriptional Programs and Inflammatory Signaling in Human Induced Pluripotent Stem Cells. [PDF]

Int J Mol Sci
Schulten W, Czaniera NJ, Fazel M, Kaltschmidt B, Kaltschmidt C.   +4 more
europepmc   +1 more source